» Articles » PMID: 24968714

Using Tramadol to Measure CYP2D6 Metabolism in Critically Ill Adults

Overview
Specialty Critical Care
Date 2014 Jun 28
PMID 24968714
Citations 2
Authors
Affiliations
Soon will be listed here.
Citing Articles

Pharmacogenetic Guided Opioid Therapy Improves Chronic Pain Outcomes and Comorbid Mental Health: A Randomized, Double-Blind, Controlled Study.

Agullo L, Aguado I, Muriel J, Margarit C, Gomez A, Escorial M Int J Mol Sci. 2023; 24(13).

PMID: 37445931 PMC: 10341655. DOI: 10.3390/ijms241310754.


CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.

Nahid N, Johnson J Expert Opin Drug Metab Toxicol. 2023; 18(11):769-785.

PMID: 36597259 PMC: 9891304. DOI: 10.1080/17425255.2022.2160317.

References
1.
Abdel-Rahman S, Leeder J, Wilson J, Gaedigk A, Gotschall R, Medve R . Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol. 2002; 42(1):24-9. DOI: 10.1177/0091270002042001002. View

2.
Frank D, Jaehde U, Fuhr U . Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol. 2007; 63(4):321-33. DOI: 10.1007/s00228-006-0250-8. View

3.
Kirwan C, Lee T, Holt D, Grounds R, MacPhee I, Philips B . Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients. Intensive Care Med. 2009; 35(7):1271-5. DOI: 10.1007/s00134-009-1430-7. View

4.
Lin Y, Lockwood G, Graham M, Brian W, Loi C, Dobrinska M . In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics. 2001; 11(9):781-91. DOI: 10.1097/00008571-200112000-00006. View

5.
Kirwan C, MacPhee I, Lee T, Holt D, Philips B . Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients. Intensive Care Med. 2011; 38(1):76-84. DOI: 10.1007/s00134-011-2360-8. View